The treatment of chronic inflammatory diseases with monoclonal antibodies against tumour necrosis factor; side effects, contraindications and precautions;De behandeling van chronische ontstekingsziekten met monoklonale antistoffen tegen tumornecrosisfactor; bijwerkingen, contra-indicaties en voorzorgen

Nederlands Tijdschrift voor Geneeskunde

Volumn 146, Issue 25, 2002, Pages 1165-1168

  Derksen, R H W M ^a   Bijlsma, J W J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ASPERGILLOSIS; CANCER INCIDENCE; CANDIDIASIS; CHRONIC DISEASE; CHRONIC INFLAMMATION; DEMYELINATING DISEASE; DRUG STRUCTURE; HEART FAILURE; HISTOPLASMOSIS; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFECTION RATE; LISTERIOSIS; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; REVIEW; TREATMENT CONTRAINDICATION; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; HUMANS; INFLAMMATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037157530     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Treatment of rheumatoid arthritis in the third millennium
2. Fatale miliaire tuberculose tijdens behandeling met infliximab
3. From bench to bedside: Discovering rules for antibody design, and improving serotherapy with monoclonal antibodies
4. Anti-TNF alpha therapy of rheumatoid arthritis: What have we learned?
5. Behandeling van reumatoïde artritis door blokkade van tumornecrosisfactor met infliximab of etanercept
6. Making antibodies by phage display technology
7. Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs
8. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies
9. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: Effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation
10. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
11. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis
12. Anti-cytokine therapy for rheumatoid arthritis
13. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: Findings in open-label and randomized placebo-controlled trials
14. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
15. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
16. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
17. Experience with etanercept in an academic medical center: Are infection rates increased?